Antares Pharma (ATRS) Earning Somewhat Favorable Media Coverage, Report Shows

News coverage about Antares Pharma (NASDAQ:ATRS) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Antares Pharma earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 44.5181565843955 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

A number of research firms have recently commented on ATRS. Piper Jaffray Companies set a $3.00 price target on Antares Pharma and gave the stock a “buy” rating in a report on Monday, October 23rd. HC Wainwright cut their price target on Antares Pharma from $5.00 to $3.50 and set a “buy” rating for the company in a report on Monday, October 23rd. ValuEngine lowered Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Finally, BidaskClub raised Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. One analyst has rated the stock with a sell rating, four have given a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $3.84.

Antares Pharma (NASDAQ:ATRS) opened at $2.23 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.34 and a quick ratio of 2.89. Antares Pharma has a twelve month low of $1.58 and a twelve month high of $4.09. The company has a market capitalization of $347.82, a price-to-earnings ratio of -20.27 and a beta of 0.25.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.03). Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The company had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.01 million. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. research analysts anticipate that Antares Pharma will post -0.11 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Antares Pharma (ATRS) Earning Somewhat Favorable Media Coverage, Report Shows” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

What are top analysts saying about Antares Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Antares Pharma and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit